An interventional study of MOBIDERM Autofit Armsleeve and Compressive bandaging in Lymphedema of Upper Limb, sponsored by Thuasne. Completed at 2 sites in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Thuasne · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Lymphedema with a site in Turkey — 12 open to participants now, 16 under way, none of them phase 3. Lymphedema · Turkey.
Among the 65 studies in Lymphedema with a site in Turkey, this one is the 23rd largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2024, is one of 44 with no phase, and was the 30th registered.
529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.
Browse Lymphedema studies →12 of the 65 studies in Lymphedema with a site in Turkey are open now. Recruiting first, the newest first:
Gazi University · Sites in Turkey
Ages 18–80
Toros University · Sites in Turkey
Ages 18–65 · Women only
Toros University · Sites in Turkey
Ages 18–65 · Women only
University Hospital, Basel, Switzerland · Sites in Turkey, United States, Austria and 8 more countries
Ages 18+
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital · Sites in Turkey
Ages 18–65
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 52 across 369 interventional studies indexed under Lymphedema.
Median enrollment 40 across the 45 interventional studies, 70 across the 20 observational. Of the 41 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 65 have an industry lead sponsor. The 10 most frequent:
Thuasne is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Thuasne has 6 studies filed under Lymphedema — fewer than ten, so there is no comparison to draw.
6 of the studies in Lymphedema with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07919093Halic UniversityComparison of the Effects of Kinesio Taping and Compression Bandaging on Edema, Range of Motion, Upper Extremity Function, and Grip Strength in Patients With Breast Cancer-Related Lymphedema | 2027-01 |
| NCT07043140Inonu UniversityMobile Self-Management Training for Lymphedema Prevention | 2027-01-30 |
| NCT07626645Gazi UniversityExtracorporeal Shock Wave Therapy in Lower Extremity Lymphedema | 2027-02-01 |
| NCT07697495Toros UniversityScapulothoracic Stabilization and Postural Training in Upper Extremity Lymphedema | 2027-03 |
| NCT07697482Toros UniversityRespiratory and Relaxation Training in Lower Extremity Lymphedema | 2027-03 |
Add all 6 to your calendar (.ics) → With an account.
Among the 65 studies in Lymphedema with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to assess Auto-Adjustable MOBIDERM® Autofit Armsleeve effect on upper limb volume excess compared to the compression bandages to manage the volume of upper limb lymphedema in patients with breast cancer related lymphedema
The overall range of compression devices dedicated to lymphedema treatment offers standard or custom-made garments and different types of bandages. Indeed, bandages are not easy to put on, requiring specific patient's skills and/or assistance which is not optimal for long-term compliance. Moreover, they are composed of several layers forming a quite bulky multilayer bandage that limits limb function and does not contribute to a better quality of life. For all these reasons described, even if bandaging is the current reference of lymphedema treatment, they have disadvantages.
The day-time elastic compressive armsleeves are proposed as an alternative to bandages. However, whatever their standard or custom-made design, they cannot adapt to limb volume/morphology evolution on the long-term management of this chronic disease because they are not adjustable. Therefore, as the comfort of treatment is very important in improving compliance, armsleeves are sometimes poorly tolerated by patients resulting in decreasing compliance to treatment plan.
In order to optimize treatment of lymphedema efficacy, THUASNE developed the standard Auto-Adjustable Armsleeve using the MOBIDERM technology.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Control group : compressive bandaging: * Intensive phase (3 weeks): compressive bandaging (day and night-time) according to the usual practice * Maintenance phase (5 weeks): usual compression sleeve during the day + Self bandages at night
Device: Compressive bandaging
Intervention group: MOBIDERM Autofit Armsleeve * Intensive phase (3 weeks): MOBIDERM Autofit Armsleeve (day and night-time) * Maintenance phase (5 weeks): usual compression sleeve during the day + MOBIDERM Autofit Armsleeve at night
Device: MOBIDERM Autofit Armsleeve
In the intervention group, during the intensive phase, patients wear day and night MOBIDERM AUTOFIT during 3 weeks. During the maintenance phase, patients wear usual compression sleeve during the day and MOBIDERM Autofit Armsleeve at night during 5 weeks
In the control group, during the intensive phase, patients wear compressive bandaging day and night-time, according to the usual practice during 3 weeks. During the maintenance phase, patients wear usual compression sleeve during the day and self bandages at night during 5 weeks
Volume excess variation
The primary endpoint of this study is to compare between both groups the volume evolution of the upper limb between inclusion and the end of the study. Limb Volume is calculated with truncated cone formula.
Time frame: 8 weeks
Resource consumption
Resource consumption is measured by time of transports (travel time in minutes).
Time frame: 3 and 8 weeks
Resource consumption
Resource consumption is measured by number of used medical devices (number).
Time frame: 3 and 8 weeks
Resource consumption
Resource consumption is measured by the number and duration (per minute) of lymphedema-related healthcare consultations and hospitalizations.
Time frame: 3 and 8 weeks
Lymphedema related Quality of life (QoL)
The evolution of QoL is measured by LYMQOL ARM self-questionnaire and specific questions. This tool is designed as patient-completed questionnaire. The questions cover four domains : symptoms, body image/appearance, function, mood. Each item in each domain is scored : not at all (1), a little (2), Quite a bit (3), A lot (4). Specific questions are about patient's perception of benefit
Time frame: 3 and 8 weeks
Doctors' opinion on improving the patient's health condition
Doctors' opinion on improving the patient's health condition caused by lymphedema is measured by the CGI-I questionnaire (Clinical Global Improvement Impression). This questionnaire allows doctors to evaluate the improvement of patients. The scale has 7 levels from "very strongly improved"(better outcome) to "very strongly aggravated"(worse outcome).Intermediate levels are: " Significantly improved " ; " Slightly improved " ; " No improvement " ; " Slightly aggravated " ; " Seriously aggravated "
Time frame: 3 and 8 weeks
Patient's opinion on Global Impression of Change
Patient's opinion on Global Impression of Change about her general condition is measured by the PGI-C questionnaire (Patient's opinion on Global Impression of Change). The scale has 7 levels from "no change or condition has got worsed"(worse outcome) to "a great deal better, and a considerable improvement that has made all the difference ( better outcome)". Intermediate levels are: "almost the same, hardly any change at all"; "a little better, but no noticeable change", "somewhat better, but the change has not made any real difference"; "moderately better, and a slight but noticeable change"; "better, and a definite improvement that has made a real and worthwhile difference
Time frame: 3 and 8 weeks
Satisfaction about the device
Patient's satisfaction with regards to MOBIDERM® Autofit vs bandages is measured by a satisfaction questionnaire. This questionnaire is focused on the product positioning with a question with 4 levels: very easy (better outcome), easy, difficult, very difficult (worse outcome) and the comfort with a question with 4 levels very comfortable (better outcome), comfortable, uncomfortable, very uncomfortable (worse outcome).
Time frame: 8 weeks
The safety
Number and type of serious and non-serious Adverse Device Effects (ADE).
Time frame: 8 weeks
Compliance to treatment
The compliance to treatment (day-time and night-time) is reported by the physician in the e-CRF according to the patient diary. The compliance is measured in number of days and or nights when the device is worn and the average wearing time
Time frame: 8 weeks
General quality of life (QoL)
The evolution of QoL is measured by the EQ5D3L questionnaire completed by the patient. The EQ-5D3L questionnaire has two components: health state description and evaluation. In the description part, health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 3 levels: no problems (Level 1 is coded as a '1'), moderate problems (Level 2 is coded as a '2'), and extreme problems (Level 3 is coded as a '3'). The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. In the evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS). The EQ VAS is measured by VAS : 100 corresponds to the best health and 0 to the the worst health.
Time frame: 3 and 8 weeks
Skin elasticity
The evolution of skin thickness and elasticity is measured by ultrasound
Time frame: 3 and 8 weeks
Ttissue induration
The evolution of tissue induration is measured via the skinfibrometer (Delfin Tech).
Time frame: 3 and 8 weeks
Plan to share: No
Ran from Mar 2024 to primary completion in Jun 2025, 15 months.
Of 197 interventional studies with no phase under Lymphedema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 64. This study's 15 months is below that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Mar 2025 → Jun 2025 and completion Apr 2025 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Thuasne